NESS-ZIONA, Israel — November 24, 2025 — Leads & Copy — Vaxil Bio Ltd. has revised the terms of its previously announced offering and now intends to complete a non-brokered private placement.
The company plans to offer up to 3,111,111 units at a price of $0.1125 per unit, aiming to raise gross proceeds of up to $350,000. Each unit will consist of one common share and one share purchase warrant. Each warrant will allow the holder to acquire one additional share at a price of $0.15 per share for five years following the offering’s closing.
The net proceeds from the offering will be used for general corporate purposes. The closing of the offering depends on several conditions, including approval by the TSX Venture Exchange.
Vaxil Bio expects the offering to close around December 4, 2025.
The company has agreed to pay finders a cash commission of up to 8% of the gross proceeds from the offering and issue non-transferable warrants of up to 8% of the aggregate number of units issued. The units, shares, warrants, and finder’s warrants will be subject to a hold period of four months and one day from their issue date, following applicable securities laws.
Vaxil was an immunotherapy biotech company focused on targeting prominent cancer markers and infectious diseases. Its lead product was ImMucin™, for which it had received orphan drug status from the FDA and EMA. The Company is presently evaluating the pursuit other business, which may or may not be in the biotechnology industry, in order to enhance shareholder value.
Gadi Levin, CEO, can be contacted at info@vaxil-bio.com or 647-558-5564.
Source: Vaxil Bio Ltd.
